NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Developing Treatments to Fight Lung Cancer

Related Editorial
After thirty years of development, gene therapy is seeing a surge of progress and profitability.

Gene therapies tackle diseases by altering the genetic makeup of patients’ cells. Recent mergers and research developments make this a promising time to invest in the sector. Gene therapy companies are developing treatments for everything from cancer and HIV to skin diseases.

Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is developing treatments to tackle lung cancer. Spark Therapeutics Inc. (NASDAQ: ONCE), which recently entered a merger agreement with the Roche Group, targets ailments such as retinal and neurodegenerative diseases. Dyadic International Inc. (OTCQX: DYAI) is focused on finding uses for a fungal-based technology that could bring treatments to market faster. TrovaGene Inc. (NASDAQ: TROV) uses cell-level treatments to tackle cancer through inhibiting a specific enzyme. The technology developed by Novartis AG (NYSE: NVS) uses specific viruses to deliver treatment for a range of illnesses.

To view the full editorial, visit http://nnw.fm/2yq0K

To hear the NetworkNewsAudio version, visit http://nnw.fm/bw1cX

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Latest News

Former Thai Prime Minister Prem Tinsulanonda dies at 98

May 26, 2019

BANGKOK — Prem Tinsulanonda, who as an army commander, prime minister and adviser to the royal palace was one of Thailand's most influential political figures over four decades, died Sunday at age 98. His death in a Bangkok hospital was announced by the government's Public Relations Department, confirming earlier unofficial reports in Thai media. Never married, he leaves no family survivors. Thai Princess Sirindhorn will preside over his initial Buddhist funeral rites on Monday. Prem was best known for his long-standing devotion to the monarchy, especially the late King Bhumibol Adulyadej, who appointed him to his Privy Council immediately after...

Arkansas newspaper gambles on free iPads as the future

May 26, 2019

HOPE, Ark. — Over a lunch of hamburger steaks, mashed potatoes and green beans, Walter Hussman delivered his pitch to the dozen or so attendees of the Hope, Arkansas, Rotary Club meeting. He promised that if they keep paying their current rate of $36 a month for subscription to the Arkansas Democrat-Gazette newspaper, even though it will no longer be printed daily or delivered to their door, they'll get a free iPad to view a digital version. The daily digital replica of the state's largest newspaper will be accessed with an easy-to-use app they can download on the tablet that...

AP FACT CHECK: Trump and a tale of 2 sheets of paper

May 26, 2019

WASHINGTON — President Donald Trump held up and read from a sheet of paper in the Rose Garden this past week as he argued he's been hounded by investigators in the Russia probe for no reason. "Nearly 500 search warrants," says the page, from an ABC News graphic. "More than 2,500 subpoenas." And: "19 special counsel lawyers & 40 FBI agents worked the case." If that sounds like overkill by the Robert Mueller inquiry, it's only half the story. Trump did not show or quote from a second page that goes with the graphic, laying out the results of the...

The Latest: Trump, in Japan, needles US ally over trade

May 26, 2019

TOKYO — The Latest on President Donald Trump's state visit to Japan. (all times local): 12:30 a.m. Sunday President Donald Trump has begun a state visit to Japan by needling the American ally over its trade imbalance with the United States. He jokingly tells business leaders at a reception in Tokyo: "Maybe that's why you like me so much." Trump also is promoting the U.S. under his leadership. He says "there's never been a better time" to invest or do business in America, and he urges corporate leaders to come. ___ 7 p.m. What stands nearly 5 feet (1.5 meters)...

Trump opens state visit, needles Japan over trade issues

May 26, 2019

TOKYO — President Donald Trump opened a state visit to Japan on Saturday by needling the country over its trade imbalance with the United States. "Maybe that's why you like me so much," he joshed. Trump also promoted the U.S. under his leadership, saying "there's never been a better time" to invest or do business in America, and he urged corporate leaders to come. The president's first event after arriving in Tokyo was a reception with several dozen Japanese and American business leaders at the U.S. ambassador's residence. He said the two countries "are hard at work" negotiating a trade...

Search

Deck Biz is an intelligent platform providing international and regional business news updates. You won’t get these insights elsewhere other than Deck Biz.

Contact us: sales@deckbiz.com